Sinopharm Group Appoints Hu Ligang As A Vice President

Published on 06/09/2025 at 06:37

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Sinopharm Group Co. Ltd.

Sinopharm Group Co. Ltd. Approves Board Appointments	Jun. 12	CI
Sinopharm Unit to Acquire 21% Stake in Pacific Shuanglin Bio-pharmacy	Jun. 10	MT
Sinopharm Group Appoints Hu Ligang As A Vice President	Jun. 09	RE
Sinopharm Group Co. Ltd Announces Resignation of Hu Ligang as Non-Executive Director, Effect from 9 June 2025	Jun. 09	CI
Sinopharm Group Co. Ltd. Announces Retirement of Mr. Li Dongjiu as Non-Executive Director, Member of the Audit Committee and A Member of the Strategy and Investment Committee, Effective May 16, 2025	May. 16	CI
Sinopharm's Q1 Profit Jumps	Apr. 28	MT
Sinopharm Group Co. Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	Apr. 28	CI
China National Accord Medicines' Q1 Profit Slips 16%	Apr. 24	MT
Sinopharm Group Posts Qtrly Net Profit Attributable RMB328 Million For Sinopharm Accord	Apr. 24	RE
Nomura Adjusts Sinopharm Group's Price Target to HK$23.40 From HK$25.09, Keeps at Buy	Mar. 25	MT
Sinopharm Group Co. Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	Mar. 23	CI
China National Accord Medicines' 2024 Profit Plunges 60%	Mar. 18	MT
Guizhou Xinbang Pharmaceutical's Subsidiary Involved in Bribery Lawsuit	Mar. 05	MT
Nomura Adjusts Sinopharm Group's Price Target to HK$25.09 From HK$28.46, Keeps at Buy	Feb. 27	MT
Sinopharm Group Co. Ltd. Approves Board Appointments	Feb. 12	CI
Sinopharm Group's Subsidiary Expects Up to 65% Lower Attributable Profit for 2024	Jan. 20	MT
Sinopharm Group Co. Ltd. Announces Board Resignations	Jan. 08	CI
Jinhai Medical Technology's Unit Authorizes Sinopharm to Solely Distribute Medical Devices in China	Jan. 03	MT
Sinopharm Group Records Lower Attributable Profit for Nine Months to September	24-10-28	MT
Sinopharm Group Co. Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024	24-10-27	CI
Sinopharm Group's Subsidiary Records 10% Lower Attributable Net Profit in Q3	24-10-23	MT
Nomura Adjusts Sinopharm Group's Price Target to HK$28.46 From HK$30.33, Keeps at Buy	24-10-18	MT
Sinopharm Group's H1 Profit Declines 10% as Revenue Drops	24-09-24	MT
Shyndec Pharmaceutical's Chairman, President Resign	24-08-28	MT
Sinopharm Group Co. Ltd. Announces Change in President	24-08-27	CI